for the ANRS CO12 CirVir Group Progenitor-derived regeneration gives rise to the aberrant expression of biliary markers such as cytokeratin 7 (K7) and patients with compensated hepatitis C virus (HCV)-related cirrhosis and to investigate its potential influence on cirrhosis complications. Among patients with Child-Pugh A uncomplicated HCV-related cirrhosis enrolled in the prospective ANRS CO12 CirVir cohort, we selected individuals with a liver biopsy collected within 2 years before inclusion in the study. K7 and EpCAM immunostaining identified intermediate hepatobiliary cells. The influence of biliary marker expression in hepatocytes on decompensation events and the occurrence of hepatocellular carcinoma (HCC) was studied using a multivariate Cox proportional hazards regression model. Among the 337 patients eligible for the study (men, 67%; median age, 52 years), 198 (58.8%) had biopsies with K7-positive hepatocytes including extensive staining in 40 (11.9%) and 203 had EpCAM-positive hepatocytes (60.6%). During follow-up (median, 54.2 months), 47 patients (14%) experienced a decompensation event, and HCC was diagnosed in 37 patients (11%). Extensive K7 staining was independently associated with the occurrence of a decompensation event (hazard ratio [HR], 3.00; 95% confidence interval [CI], 1.30-6.89; P 5 0.010). EpCAM expression was independently associated with HCC occurrence (HR, 2.37; 95% CI, 1.07-5.23; P 5 0.033) along with age and a low prothrombin ratio. Conclusion: Progenitor-derived regeneration depicted by K7 and EpCAM immunostaining of hepatocytes in liver biopsies of patients with compensated HCV-related cirrhosis marks a cirrhosis stage more prone to develop complications. (HEPATOLOGY 2018; 68:1534-1548).
I
n Western countries, chronic infection with hepatitis C virus (HCV) is the leading viral cause of cirrhosis.
(1) Two large longitudinal prospective cohorts clarified the natural history of patients with HCV-related advanced liver fibrosis and reported high frequencies of life-threatening complications. (2, 3) The prediction of hepatocellular carcinoma (HCC) risk and the occurrence of complications in patients with earlystage cirrhosis remain ongoing challenges, requiring improvements in current stratification risk. In the era of highly efficacious therapies for HCV, (4, 5) it becomes essential to identify patients with HCV-related cirrhosis who are at higher risk of developing progressive disease and HCC, taking into account virosuppression. The study of cirrhosis at the cellular and molecular levels might predict major liver-related endpoints, including HCC development, liver disease progression, liver transplantation, and death, beyond clinically available prognostic indicators but could also highlight specific points of dysregulation that can guide therapeutic or preventive interventions. The liver possesses a marked capacity to regenerate following injury, and this regeneration usually occurs due to the division of mature hepatocytes. However, in severe and/or chronic liver diseases, regeneration can result from progenitor cells located along the intralobular bile ductule and along the canals of Hering. (6) This "abnormal" regeneration gives rise to a specific "transitional" compartment, known as intermediate hepatobiliary cells, which are characterized as small hepatocytes that express cytokeratin 7 (K7)-a marker of the biliary epithelium-while mature hepatocytes are negative for K7. (7) This hepatocyte regeneration pathway expands the stem cell compartment and makes these cells more prone to carcinogenesis, as suggested by experimental models (8, 9) and in vitro studies. (10, 11) In a retrospective monocentric study of 150 patients with HCV-related cirrhosis and active viral replication, we described that the aberrant expression of K7 biliary markers in hepatocytes was related to HCC occurrence. (12) The influence of epithelial cell adhesion molecule (EpCAM), another molecule expressed in early hepatocytes derived from the progenitor cell compartment, (13) lost in as few as two cell divisions (14) on cirrhosis prognosis, had not been investigated. We aimed to describe the progenitor-derived regeneration, depicted by K7 and EpCAM expression in hepatocytes, in a prospective multicentric cohort comprising patients with compensated HCV-related cirrhosis and to investigate the potential influence of this aberrant expression on decompensation events and on the occurrence of HCC.
Patients and Methods
This is an ancillary study derived from the CirVir cohort (3) with its own funding from the ANRS. This protocol was approved by the ethics committee (Comit e de Protection des Personnes, Aulnay-sous-Bois, France) and conformed to the ethical guidelines of the 1975 Declaration of Helsinki. All patients gave written informed consent before participating in the study. The full CirVir protocol is available on the ANRS website (http://anrs.fr).
PATIENTS
Among patients with biopsy-proven compensated (Child-Pugh A) and uncomplicated virus-related cirrhosis who were enrolled in the French multicenter ANRS CO12 CirVir cohort between March 2006 and July 2012 and who were prospectively followed up for the development of HCC, (3) only those with HCV (i.e., positive for HCV antibodies at any level of viral replication) either with or without hepatitis B virus coinfection were selected for this ancillary study. The second inclusion criterion for this ancillary study was an available liver biopsy (LB) performed within 2 years before study enrollment. The location, date, and identification number of the LB confirmed that a diagnosis of cirrhosis was recorded upon enrollment. When LBs were performed within 2 years before study enrollment, pathologists at the different clinical centers were asked to send unstained slides or blocks of the liver biopsy sample for the purposes of the present study. 
BASELINE

FOLLOW-UP AND HCC DIAGNOSIS
Follow-up was scheduled according to French guidelines (Haute Autorit e de Sant e). Doppler ultrasound examination was performed every 6 months for HCC screening. In cases where focal liver lesions were detected by ultrasound, a diagnostic procedure using contrast-enhanced imaging (computed tomographic scan or magnetic resonance imaging), serum AFP assay, and/or guided biopsy were performed according to 2005 American Association for the Study of Liver Diseases (AASLD) guidelines, (15) updated in 2011. (16) An HCC diagnosis was established either by histological examination performed by an experienced pathologist or by using probability-based noninvasive criteria (mainly dynamic imaging showing early arterial hypervascularization and portal washout) according to the different periods of time (before and after 2011). When an HCC diagnosis was established, treatment was decided using a multidisciplinary approach according to either AASLD or European Association for the Study of the Liver guidelines for HCC. (15) (16) (17) Reports of imaging techniques showing liver focal lesions were secondarily reviewed by the two senior hepatologists (V.B. and P.N.).
All events occurring during follow-up (liver-related or not) were recorded based on information obtained from the medical files of patients from each center. In particular, all episodes and the severity of liver decompensation encompassing ascites, hepatic encephalopathy, and gastrointestinal bleeding were described; these episodes were managed according to international recommendations and outcome. (18, 19) All extrahepatic events occurring during follow-up were also recorded. Likely causes of death were established. Patients who underwent liver transplantation were censored (or considered to be lost to follow-up) at the date of transplantation for the analysis. All treatments that included antiviral therapy were recorded at inclusion, and any modification during follow-up was noted. According to the time of enrollment, patients received varying antiviral treatments approved by either national or international guidelines, as described (20) ; and the subsequent sustained virological response (SVR) was recorded when achieved. The main endpoints of the study were the occurrence of HCC and/or an initial first decompensation event. The time frame was defined as the time from the date of inclusion until the first decompensation and/or HCC detection. Followup for this ancillary study ended at the date of either the first decompensation event or a diagnosis of HCC, at the date of liver transplantation, at the date of death due to causes other than HCC and decompensation, or at the last recorded visit through December 31, 2015.
HISTOLOGY AND IMMUNOHISTOCHEMISTRY
LB specimens were previously formalin-fixed and paraffin-embedded. Dewaxed and rehydrated paraffin sections (3 lm thick) were stained with hemateineosin and picrosirius red. Immunostaining was performed using a standardized immunoperoxidase method with an anti-K7 monoclonal antibody (DakoCytomation; anti-K7 antibody OV-TL 12/30, 1/50 dilution with prior antigen retrieval, ethylene diamine tetraacetic acid [pH 9]) and an anti-EpCAM monoclonal antibody (Novocastra-Leica; NCL-MOC31, 1/ 25 dilution with prior antigen retrieval, 10 mM citrate buffer [pH 6]) with an automated staining system (Leica; Novolink-polymer detection system, Dako autostainer).
Hematein-eosin-stained liver biopsy samples were assessed for steatosis (grade 0, <5%; grade 1, 5%-33%; grade 2, 33%-66%; grade 3, >66%), activity according to the METAVIR scoring system, and ballooning (grade 0, absent; grade 1, size of ballooned hepatocytes <2-fold that of a normal hepatocyte; grade 2, size >2-fold) as described in the steatosis/activity/fibrosis score. (21) The presence of alcoholic hepatitis, which was defined by the association of liver cell ballooning, polymorphonuclear infiltrates, and Mallory bodies, (22) was also reported. We considered that steatohepatitis was associated with virus-related cirrhosis when we observed both steatosis involving >5% of hepatocytes and a clear ballooning grade of 1 or 2. As described, (12) hepatocytes were considered to express K7 when at least two foci of more than five polygonal-shaped hepatocytes measuring 6-40 l in diameter were detected. K7 staining was considered extensive when one or several cirrhotic nodules showed positive staining in >30% of hepatocytes. Hepatocytes were considered positive for EpCAM when a focus of more than three positive contiguous hepatocytes was detected. Hematein-eosin-stained and immunostained sections were all independently assessed by two pathologists (D.W., M.Z.). In cases of disagreement, sections were reexamined using a multipipe microscope, and consensus was reached, which was used for the final analysis.
To further characterize K7 and EpCAM expression, we also studied the liver biopsies of 39 patients who had sequential biopsies (the first one at the time of HCV-related cirrhosis diagnosis and the second at the time of HCC diagnosis), of 28 patients with HCV chronic hepatitis under the cirrhosis stage, of 16 obese patients with normal liver, and of 12 patients with steatohepatitis without cirrhosis.
STATISTICAL ANALYSES
Descriptive results are presented as the means 6 standard deviation or medians (interquartile range [IQR]) for continuous variables and as numbers (percentages) for categorical variables. Baseline characteristics were compared among groups of patients with or without biliary markers using either the Student t test or the Mann-Whitney/Kruskal-Wallis test for continuous variables. Categorical variables were compared using the v 2 test or Fisher's exact test when necessary. Curves of the cumulative incidence of HCC and decompensation as well as survival curves were constructed using the Kaplan-Meier method and compared according to the expression of biliary markers using the log-rank test. The influence of all potential features (including the expression of biliary markers) on the occurrence of HCC, decompensation events, and overall and specific mortality was assessed using a Cox proportional hazards regression model in the univariate analyses. In the multivariate analysis, the final model was built in several steps: (1) all parameters with a P value <0.20 in univariate analysis were included in a model, (2) from this model, we excluded one by one each nonsignificant parameter with a P value >0.05 to finally obtain a final multivariate model only containing significant factors independently associated with the studied outcome. All of the predictors were assessed based on their baseline levels with the exception of SVR, which was included as a time-varying covariate in all Cox models to account for the fact that SVR may occur at different time points. Fixed SVR values were used for patients who never experienced SVR (SVR 5 0) and patients who achieved SVR at the time of their enrollment (SVR 5 1). Non-SVR patients at enrollment who achieved SVR status during follow-up were switched from non-SVR to SVR status. The final treatment that led to undetectable HCV RNA was set as the time point for switching the SVR values from 0 to 1. No reinfection or relapse as defined by detectable HCV RNA in a patient who previously achieved SVR was observed during the follow-up.
All statistical analyses were performed using Stata 13.0 (StataCorp, College Station, TX). P 0.05 was considered statistically significant.
Results
PATIENT SELECTION
Among the 1,354 patients with compensated HCVrelated cirrhosis who were prospectively included in the ANRS CO12 CirVir study from 2006 to 2012, (3) 853 were excluded because the LB was performed more than 2 years before enrollment, and 157 were further excluded because the LB sample had not been sent by the pathology laboratory (Fig. 1) . Seven patients were excluded because of failed K7 and EpCAM immunostainings. Analyses were performed in the remaining 337 patients. The selected patients with an available LB for immunostaining had baseline characteristics similar to those observed in the whole cohort except for age (median age was 52 in the selected patients versus 55 in the whole cohort, P < 0.001).
LB ANALYSIS AND BASELINE CHARACTERISTICS
The LBs consisted of 1-12 fragments (mean 3) with a mean total size of 18 mm (range, 3-44). Cirrhosis was confirmed in all of the biopsy samples. Necroinflammatory activity was moderate or severe in 156 patients (46.3%). Steatohepatitis was observed in 141 patients (41.8%) and alcoholic hepatitis in 7 (2.1%). No histological cholestasis was observed. Focal K7 staining was detected in 158 patients (46.9%) and extensive K7 staining (Fig. 2 ) in 40 patients (11.9%). EpCAM was localized to the membrane of periseptal hepatocytes in 203 patients (60.6%). The kappa interobserver agreement for the K7 and EpCAM assessment was 0.74 (95% confidence interval [CI], 0.67-0.81) and 0.74 (95% CI, 0.65-0.82), respectively. The extent of EpCAM staining was variable from one focus to extensive staining of several rows of hepatocytes at the borders of the cirrhotic nodules (Fig. 2) . K7 (either focal or extensive) and EpCAM stainings in the hepatocytes were highly correlated (P < 0.001), and both stains were often localized to the same cirrhotic nodules and in the same areas of the cirrhotic nodules. Serial sections of the biopsies showed that the two stains were not strictly colocalized at the cellular level because EpCAM-stained hepatocytes tended to surround a K7-stained hepatocyte and some EpCAM hepatocytes present within the first rows of some cirrhotic nodules lost their EpCAM expression but then acquired CK7 (Fig. 2) . On the other hand, K7-positive or EpCAM-positive hepatocytes could also be detected independently in a noncontiguous manner. Moreover, K7 foci frequently colocalized with periportal lymphocytic infiltrate, while EpCAM staining did not. K7 and EpCAM were frequently observed in steatohepatitis foci but also independently of steatohepatitis foci. The detection of K7-stained and EpCAMstained hepatocytes in LBs according to the baseline clinical, biological, and histological characteristics of patients is described in Tables 1 and 2 , respectively. The presence of K7 and the presence of EpCAM were significantly related to higher AFP levels, a lower platelet count, higher GGT levels, lower albumin levels, and a reduced prothrombin ratio. However, only K7 staining was associated with higher ALT levels. Regarding clinical characteristics, K7 and EpCAM were not related to age, alcohol intake (past or at inclusion), alcoholic hepatitis, diabetes, or BMI. Only female gender was slightly associated with K7 staining. Regarding histological criteria, concomitant K7 and EpCAM expression was strongly associated with steatohepatitis, but only CK7 was strongly related to the activity grade. Characteristics of patients according to the presence of a histological steatohepatitis are given in Supporting Table S3 . Patients with steatohepatitis were younger and had metabolic syndrome and higher BMI, ALT levels, and AST levels.
In 39 patients (13 from this cohort study) with sequential biopsies (mean time between biopsies, 5 years), EpCAM and K7 status (negative or positive) were constant in 29 (74%) and 27 patients (69%), respectively, while either disappearance or emergence of these markers occurred in other cases. No K7 or EpCAM was observed in the 16 normal livers; in the 28 cases of HCV chronic hepatitis with F1, F2, and F3 METAVIR fibrosis stage; and in 11 out of 12 cases of nonalcoholic steatohepatitis with F1, F2, and F3 fatty liver inhibition of progression fibrosis stages. EpCAM stained the membrane of contiguous hepatocytes (C,D, arrows) preferentially at the border of the cirrhotic nodules when detected. EpCAM also stained some ductules (stars, C). EpCAM-stained and K7-stained intermediate hepatocytes were observed in the same cirrhotic nodules as shown in this example with serial sections (white arrows in A,C). However, at the cellular level, both stainings (B,D) were not stackable, and EpCAM-positive areas encompassed K7-stained hepatocytes. The clinical, biological, and histological baseline characteristics associated with the occurrence of liver decompensation are described in Table 3 . Based on the P < 0.20 cutoff from the univariate analysis, the biological and histological variables potentially related to the occurrence of liver decompensation were albumin level 35 g/L, total bilirubin >17 lmol/L, platelet count <100 3 10 3 /mm 3 , GGT >2 times the upper limit of normal, prothrombin ratio 80%, higher AFP levels, diabetes, esophageal varices, absence of SVR, histological alcoholic hepatitis, and expression of K7 in the LB. EpCAM expression was not associated with a higher risk of liver decompensation. Based on the multivariate analysis, total bilirubin level >17 lm/L, albumin level 35 g/L, absence of SVR, and K7 staining (extensive: hazard ratio [HR], 3.00; 95% CI, 1.30-6.89; P 5 0.010) remained independently related to the occurrence of a liver decompensation event. Seven patients who achieved SVR experienced a decompensation event. The incidence of decompensation during a 3-year follow-up was 19.6% in patients with extensive K7 staining compared to 3.9% in patients without K7 staining (Fig. 3) . When non-SVR patients were selected (n 5 304, 28 decompensation events), multivariate analysis showed results similar to those observed in the whole cohort, with albumin, total bilirubin, and K7 being related to decompensation (Supporting Table S4 ). In patients with SVR at endpoint (n 5 187, eight decompensation events), no clinical, biological, or histological variables were related to decompensation.
INFLUENCE OF HISTOLOGICAL CHARACTERISTICS ON LIVER DECOMPENSATION
INFLUENCE OF HISTOLOGICAL CHARACTERISTICS ON HCC OCCURRENCE
HCC was diagnosed in 37 patients (11.0%), and the median time of occurrence was 33.4 months (IQR, 25.8-45.5). Among them, 28 HCCs occurred in patients without SVR and 9 in patients who achieved SVR. Baseline biological and histological variables with P < 0.20 in the univariate analysis that were potentially related to the occurrence of HCC were age, a lower prothrombin ratio, lower platelet counts, lower albumin levels, higher AFP levels, higher GGT levels, the absence of SVR, and the presence of EpCAM-stained hepatocytes in the LB. K7 expression was not associated with a higher risk of HCC. The multivariate analysis showed that age, prothrombin ratio, and EpCAM-positive hepatocytes in the LB (HR, 2.37; 95% CI, 1.07-5.23; P 5 0.033) remained independently related to HCC occurrence (Table 4) . Detection of EpCAMstained hepatocytes upon study enrollment was significantly associated with HCC occurrence (Fig.  3) . After 50 months of follow-up, the cumulative incidence of HCC reached 15.1% in EpCAMpositive patients versus 7.4% in EpCAM-negative patients. We further investigated the influence of K7 on HCC risk in patients with and without SVR during follow-up and found that the presence of K7 staining (focal and/or extensive) was significantly related to HCC occurrence in patients without SVR (P 5 0.048), but it was not related to HCC in patients with SVR (Supporting Table S5 ). 
INFLUENCE OF HISTOLOGICAL CHARACTERISTICS ON SURVIVAL
During follow-up, 36 patients died, and 19 deaths were liver-related (8 decompensation or liver failure, 5 HCC, 1 cholangiocarcinoma, 5 variceal bleeding). Five patients died from severe non-spontaneous bacterial peritonitis infection. Eight patients have been transplanted. Based on variables with P < 0.20 in the univariate analysis, overall survival was potentially related to age, albumin level, AFP levels, ALT levels, steatosis, the absence of steatohepatitis, the presence of alcoholic hepatitis, the absence of SVR, and K7 staining (focal or extensive). The multivariate analysis showed that K7 staining (focal: HR, 3.49; 95% CI, 1.47-8.29; P 5 0.005), absence of SVR (HR, 2.63; 95% CI, 1.10-6.25; P 5 0.029), and absence of steatohepatitis (HR, 2.70; 95% CI, 1.30-5.88; P 5 0.009) were independent variables related to overall death. These results are detailed in Supporting Table S1 and Figs. S1 and S2. Liver-related deaths including HCC and bacterial infection were potentially related to older age; BMI; AFP levels; platelet counts; albumin level; prothrombin ratio; the absence of steatohepatitis; histological alcoholic hepatitis; and the absence of SVR, EpCAM, and K7 staining based on the univariate analysis (P < 0.20). The multivariate analysis showed that obesity, the absence of SVR, lower platelet counts, the absence of steatohepatitis, and K7 staining (either focal or extensive) were independently related to liver-related deaths (Supporting Table S2 ).
Discussion
In this large prospective national cohort of patients with compensated HCV-related cirrhosis, the expression of progenitor-derived regeneration markers such as K7 and EpCAM in hepatocytes was observed in 58.8% and 60.6% of 337 LBs, respectively. Normal liver, HCV chronic hepatitis, and nonalcoholic steatohepatitis without cirrhosis were always negative for these markers. Expression of both markers was related to the presence of steatohepatitis and liver dysfunction biological markers. We found that extensive K7 staining, which was observed in 40 patients (11.9%), was independently associated with the occurrence of a decompensation event (HR, 3.00; 95% CI, 1.30-6.89; P 5 0.010), while EpCAM expression was independently associated with HCC occurrence (HR, 2.37; 95% CI, 1.07-5.23; P 5 0.033).
We previously described the aberrant expression of biliary markers and reported a correlation between K7 expression and HCC occurrence. The goal of the present study was to validate our previous observation on a larger and prospective cohort with LBs processed at different centers. Surprisingly, the expression of K7, when assessed according to the same criteria, could predict decompensation but not HCC occurrence. The explanation for this apparent discrepancy may rely on the major changes of antiviral treatment efficacy. In our previous study, all 150 subjects presented active ongoing HCV infection, and patients who cleared HCV infection during follow-up were excluded from that study. In the present study, which reflects the dramatic changes in the treatment efficacy and tolerance in patients with cirrhosis, 191 of 331 patients (57.7%) achieved SVR. Given that SVR significantly decreases HCC occurrence, (4, 20, 23, 24) it is not surprising that the baseline biomarkers observed in the first study were no longer predictive in the present prospective cohort. In accordance with the first study, the presence of K7 staining (focal or extensive) remained significantly related to HCC occurrence in patients without SVR (P 5 0.048). In the previous study, we did not investigate the influence of K7 on decompensation and did not perform EpCAM immunostaining. The combined results of both studies suggest that the presence of K7 foci at baseline reflects an ongoing active progenitorderived regeneration that favors carcinogenesis in patients with persistent viral infection but not in patients who cleared infection. Whether clearing infection leads to a reversion of the aberrant K7 phenotype has not been investigated by sequential biopsies, but D'Ambrosio et al. (25) showed reversal of several parameters such as zonation and ductular proliferation in a sequential pretreatment and posttreatment paired biopsy study. Moreover, the presence of K7 foci was related to ALT levels and to the activity score. We could hypothesize that periportal lymphocytic infiltrate induces, after hepatocytes apoptosis, a signal for abnormal regeneration from progenitor cells in the same zone or a transdifferentiation of mature hepatocytes. The aberrant phenotype induced by necrotic and inflammatory activity of viral hepatitis would be reversed by viral eradication and could consequently lower the ability of K7 expression to predict a higher risk of HCC occurrence. However, sequential biopsies, which were not performed in this study, would have been required to prove this hypothesis.
A striking finding of our study was the strong relationship between extensively K7-stained cirrhotic developing cirrhosis complications and liver-related death independent of SVR. Thus, aberrant phenotypes that reflect abnormal progenitor-derived regeneration and/or transdifferentiation of hepatocytes in biopsies could represent a practical readout of the cirrhosis stage at risk for complications in patients who do not achieve SVR, even though the interobserver agreement of K7 and EpCAM was not perfect (kappa 5 0.74, fair to good). Its prognostic value in patients with SVR remains to be determined. The demonstration of the link between phenotypic alterations of hepatocytes, exclusively observed in cirrhosis, and the occurrence of complications could also open the way for the search of peripheral blood markers, of circulating EpCAMpositive or CK7-positive hepatocytes, and for antiEpCAM vaccination. (36) 
